MOTS-c vs Rusfertide
Overview
MOTS-c and Rusfertide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares MOTS-c and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| MOTS-c | Rusfertide | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 5-10 mg | 19-108 mg |
| Frequency | weekly | once weekly, subcutaneous |
| Reported benefits | Enhanced metabolism, improved insulin sensitivity, increased exercise capacity, longevity benefits | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | Well-tolerated. Minimal reported side effects | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. MOTS-c is categorised under Weight Management & Metabolic, while Rusfertide falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. MOTS-c: not FDA-approved; compounding permitted with a prescription as of April 2026. Rusfertide: FDA-approved.
Dosing. MOTS-c is typically dosed at 5-10 mg (weekly). Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking MOTS-c and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between MOTS-c and Rusfertide?
- MOTS-c and Rusfertide are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Rusfertide is FDA-approved for one or more indications.
- What is MOTS-c used for?
- Mitochondrial optimization.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take MOTS-c and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking MOTS-c and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is MOTS-c or Rusfertide FDA-approved?
- MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026). Rusfertide is FDA-approved for one or more indications.
Read the full articles
- MOTS-c — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references